In-vitro assembly method of human-derived compound N-glycopeptide

By expressing and using the oligosaccharide transferase TbSTT3A catalyzed in insect cells, the complex N-saccharide chain was transferred to the polypeptide, solving the problem of preparing uniform N-glycopeptides in vitro, and achieving efficient assembly and structure of glycoproteins Uniformity has promoted the development of sugar chemistry and sugar biology.

CN119040291APending Publication Date: 2024-11-29JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310617222.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prepare uniform human N-glycopeptides/proteins in vitro, and the uneven structure of the sugar chain affects the quality and efficacy of glycoproteins, resulting in limited application of glycoproteins in the treatment of human diseases.

Method used

The oligosaccharide transferase TbSTT3A is used to express in insect cells and catalyze the transfer of complex N-saccharide chains from fatty alcohol oligosaccharides to the polypeptides to achieve in vitro assembly of human complex N-saccharides, using HEPES and MnCl2 and other conditions. Optimize the reaction system to ensure the uniformity of the sugar chain structure.

Benefits of technology

It realizes the efficient assembly of human complex N-glycopeptides, provides a new solution to target the construction of human N-glycopeptides, promotes the development of sugar chemistry and sugar biology, and promotes the human N-glycope chain structure organisms Activity research and development of glycoprotein drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040291A_ABST
    Figure CN119040291A_ABST
Patent Text Reader

Abstract

The invention discloses an in-vitro assembly method of human-derived compound N-glycopeptide. The in-vitro assembly method comprises the following steps: expressing trypanosoma buchneri-derived oligosaccharyl transferase TbSTT3A in insect cells; the preparation method comprises the following steps of: transferring oligosaccharide in fatty alcohol oligosaccharide containing an N-carbohydrate chain to human polypeptide by utilizing catalysis of oligosaccharyl transferase TbSTT3A, so as to obtain human compound N-glycopeptide; wherein the oligosaccharyl transferase TbSTT3A gene has a nucleotide sequence as shown in SEQ ID NO. 1 (sequence identifier number 1). According to the invention, the TbSTT3A with high substrate adaptability is utilized to directly transfer the composite N-sugar chain onto the human polypeptide chain for the first time, efficient assembly of the human N-glycopeptide / glycoprotein modified by the specific structure sugar chain is realized, and the method has important significance for comprehensively analyzing the biological activity of the human N-sugar chain structure and developing the production technology of glycoprotein drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biochemistry, and specifically relates to an in vitro assembly method of human composite N-glycopeptide. Background Art

[0002] Glycosylation is one of the post-translational modifications of eukaryotic cells, which has an important impact on the structure and function of proteins. 70% of the cell membrane surface glycoproteins and secretory glycoproteins in the human body have complex N-glycans, which means that the N-glycan modification of a specific structure plays an irreplaceable role in the biological function of human glycoproteins, but the complex in vivo environment leads to the diversity of glycosylation modifications, so that many glycoprotein structure / function relationships and their regulatory mechanisms have yet to be discovered and confirmed. In addition, glycoproteins have been used to treat human diseases, but the problem of uneven sugar chain structure caused by the existing cell production system, which affects the quality and efficacy of glycoproteins, has not been solved so far. At present, it is difficult to obtain uniform N-glycopeptides / proteins. Although some progress has been made in the research on in vitro chemical synthesis or chemical enzyme assembly of uniform N-glycopeptides, the existing methods still have shortcomings such as complex chemical synthesis process and the need for appropriate initial sugar chain structure on the protein. Therefore, the development of a new and universal composite N-glycopeptide / protein assembly strategy will provide a powerful tool for the precise and efficient preparation of various human homogeneous glycoproteins, which has important scientific significance for comprehensively analyzing the biological activity of human N-sugar chain structures, studying the pathological mechanisms of related biomarkers, and developing production technologies for glycoprotein drugs. Summary of the invention

[0003] The purpose of this section is to summarize some aspects of embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.

[0004] In view of the above problems and / or the problems existing in the prior art, the present invention is proposed.

[0005] One of the objectives of the present invention is to provide an in vitro assembly method for human composite N-glycopeptides, using oligosaccharyltransferase TbSTT3A to catalyze the transfer of composite N-glycans from fatty alcohol oligosaccharides to various human polypeptides, thereby successfully preparing homogenized N-glycopeptides.

[0006] In order to solve the above technical problems, the present invention provides the following technical solutions: an in vitro assembly method of human composite N-glycopeptide, comprising:

[0007] Expression of Trypanosoma brucei-derived oligosaccharyltransferase TbSTT3A in insect cells;

[0008] Using oligosaccharyl transferase TbSTT3A to catalyze the transfer of oligosaccharides from fatty alcohol oligosaccharides containing N-sugar chains to polypeptides, humanized composite N-glycopeptides were obtained.

[0009] Wherein, the oligosaccharyl transferase TbSTT3A gene has a nucleotide sequence as shown in SEQ ID NO.1.

[0010] As a preferred embodiment of the in vitro assembly method of the human composite N-glycopeptide of the present invention, wherein: the catalytic reaction system further contains HEPES and MnCl2;

[0011] Relative to the 50 μL system, the final concentration of HEPES is 20 mM, the final concentration of MnCl2 is 10 mM, the final concentration of polypeptide is 10 μM, the final concentration of fatty alcohol oligosaccharide is 10-20 μM, the final concentration of TbSTT3A is 20 nM, and the reaction time is 2-12 h.

[0012] As a preferred embodiment of the in vitro assembly method of the humanized composite N-glycopeptide of the present invention, the fatty alcohol oligosaccharides containing N-sugar chains are various fatty alcohol oligosaccharides obtained by catalysis of recombinant glycosyltransferases Alg1, Alg2, GnT-I, GnT-II, GalT and FuT expressed in Escherichia coli using PPGn2 as the starting substrate.

[0013] As a preferred embodiment of the in vitro assembly method of the humanized composite N-glycopeptide of the present invention, the fatty alcohol oligosaccharide containing the N-sugar chain is selected from one of PPGn2Man3Gn, PPGn2Man3GnGal, PPGn2Man3Gn(Fuc)Gal, PPGn2Man3Gn2, and PPGn2Man3Gn2Gal2.

[0014] As a preferred embodiment of the in vitro assembly method of the human composite N-glycopeptide of the present invention, the polypeptide comprises a model polypeptide STD and various human polypeptides; the human polypeptides include but are not limited to one of a human IgG polypeptide fragment and a human EPO polypeptide fragment.

[0015] As a preferred embodiment of the in vitro assembly method of the human composite N-glycopeptide of the present invention, wherein: the polypeptide sequence of the model polypeptide STD is 5CF-GSDANYTYTQ-NH2;

[0016] The human IgG polypeptide fragment is a human IgG polypeptide 297 , whose polypeptide sequence is 5CF-EEQYN 297 STYRV-NH2;

[0017] The human EPO polypeptide fragment is a human polypeptide EPO38 , whose polypeptide sequence is 5CF-SLNEN 38 ITVPD-NH2.

[0018] As a preferred scheme of the in vitro assembly method of the humanized complex N-glycopeptide of the present invention, the model polypeptide (STD) is used as a substrate, different fatty alcohol oligosaccharides (PPGn2Man3Gn, PPGn2Man3GnGal, PPGn2Man3Gn(Fuc)Gal, PPGn2Man3Gn2, PPGn2Man3Gn2Gal2) are added to the system, and under the catalytic action of TbSTT3A, glycopeptides such as GnMan3Gn2-STD, GalGnMan3Gn2-STD, GalGn(Fuc)Man3Gn2-STD, Gn2Man3Gn2-STD, and Gal2Gn2Man3Gn2-STD are obtained respectively.

[0019] As a preferred embodiment of the in vitro assembly method of the human composite N-glycopeptide of the present invention, the human IgG polypeptide fragment is used as a substrate, different fatty alcohol oligosaccharides (PPGn2Man3Gn, PPGn2Man3GnGal, PPGn2Man3Gn(Fuc)Gal, PPGn2Man3Gn2, PPGn2Man3Gn2Gal2) are added to the system, and under the catalytic action of TbSTT3A, GnMan3Gn2-IgG is obtained respectively. 297 , GalGnMan3Gn2-IgG 297 , GalGn(Fuc)Man3Gn2-IgG 297 , Gn2Man3Gn2-IgG 297 , Gal2Gn2Man3Gn2-IgG 297 Glycopeptides.

[0020] As a preferred embodiment of the in vitro assembly method of the human composite N-glycopeptide of the present invention, when the human EPO polypeptide fragment is used as the substrate, different fatty alcohol oligosaccharides (PPGn2Man3Gn, PPGn2Man3GnGal, PPGn2Man3Gn(Fuc)Gal, PPGn2Man3Gn2, PPGn2Man3Gn2Gal2) are added to the system, and under the catalytic action of TbSTT3A, GnMan3Gn2-EPO is obtained respectively. 38 , GalGnMan3Gn2-EPO 38 , GalGn(Fuc)Man3Gn2-EPO 38 , Gn2Man3Gn2-EPO 38 , Gal2Gn2Man3Gn2-EPO 38 Glycopeptides.

[0021] As a preferred embodiment of the in vitro assembly method of the humanized composite N-glycopeptide of the present invention, the oligosaccharyltransferase TbSTT3A is an oligosaccharyltransferase STT3A with 8*His and StrepII tags fused to the N-terminus, and the oligosaccharyltransferase STT3A is derived from Trypanosoma brucei.

[0022] As a preferred embodiment of the in vitro assembly method of the humanized composite N-glycopeptide of the present invention, the oligosaccharyl transferase TbSTT3A derived from Trypanosoma brucei is expressed in insect cells, comprising:

[0023] According to the nucleic acid sequence of oligosaccharyl transferase STT3A from Trypanosoma brucei, a vector was constructed using gene synthesis technology and fusion PCR, and then coated on the corresponding resistance screening plate, and the single clones with positive colony PCR were selected, and the plasmid was extracted and sent for sequencing to obtain oligosaccharyl transferase TbSTT3A;

[0024] The TbSTT3A gene fragment was constructed into the plasmid pFastBac1 to obtain the recombinant plasmid pFastBac1-8His-strepII-TEV-STT3A;

[0025] The recombinant plasmid pFastBac1-strepII-TEV-STT3A was transformed into the competent cell DH10BAac, and the recombinant STT3A bacmid was extracted. After PCR verification, the recombinant STT3A bacmid was transferred into insect SF9 cells using a liposome transfection reagent to obtain the first-generation virus. The first-generation virus was then used to infect SF9 cells to obtain the second-generation virus. Finally, the second-generation virus was used to infect SF9 cells. After culture, the cells were collected, lysed, and purified by Strep affinity chromatography. The expression and purity of the TbSTT3A protein were confirmed by SDS-PAGE.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] The present invention skips the complex biosynthetic pathway of human N-glycochains in vivo, synthesizes a variety of fatty alcohol oligosaccharides containing human complex N-glycochains in vitro, and then uses the oligosaccharyltransferase TbSTT3A with high substrate adaptability to catalyze the transfer of complex N-glycochains from fatty alcohol oligosaccharides to various human polypeptides, thereby achieving efficient assembly of uniform human N-glycopeptides modified with specific structural sugar chains, providing a new solution for the directional construction of human N-glycopeptides and promoting the development of glycochemistry and glycobiology. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:

[0029] Figure 1 This is a SDS-PAGE Coomassie blueprint of the purified oligosaccharyltransferase TbSTT3A protein.

[0030] Figure 2 Five glycopeptide maps were generated for the model peptide STD catalyzed by oligosaccharyltransferase TbSTT3A; A is the flow chart and B is the liquid phase result map.

[0031] Figure 3 MS results of five glycopeptides generated for the model peptide STD catalyzed by oligosaccharyltransferase TbSTT3A.

[0032] Figure 4 Oligosaccharyl transferase TbSTT3A catalyzes the production of human peptide IgG 297 Five glycopeptide maps were generated; A is the flow chart and B is the liquid phase result map.

[0033] Figure 5 Oligosaccharyl transferase TbSTT3A catalyzes the production of human peptide IgG 297 Generate MS result plots for 5 glycopeptides.

[0034] Figure 6 The oligosaccharyl transferase TbSTT3A catalyzes the production of human peptide EPO 38 Five glycopeptide maps were generated; A is the flow chart and B is the liquid phase result map.

[0035] Figure 7 Oligosaccharyl transferase TbSTT3A catalyzes the production of human peptide EPO 38 Generate MS result plots for 5 glycopeptides.

[0036] Figure 8 The liquid phase results of oligosaccharyltransferase TbSTT3A catalyzing the production of glycopeptides from human polypeptides at different times; A represents three glycopeptides produced in 30 minutes, and B represents three glycopeptides produced in 1 hour. DETAILED DESCRIPTION

[0037] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.

[0038] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0039] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The term "in one embodiment" that appears in different places in this specification does not necessarily refer to the same embodiment, nor does it refer to a separate or selective embodiment that is mutually exclusive with other embodiments.

[0040] The reagents involved in the examples: restriction endonucleases, Prime Star DNA polymerase, ligase, etc. were purchased from Takara Biotechnology Co., Ltd. (Dalian), Japan; plasmid extraction kit and IPTG were purchased from Shanghai Bioengineering; sequencing was performed by Andasheng in Suzhou.

[0041] The fatty alcohol oligosaccharides containing N-sugar chains were obtained by referring to the method in patent CN114958943A: PPGn2Man3Gn, PPGn2Man3GnGal, PPGn2Man3Gn(Fuc)Gal, PPGn2Man3Gn2 and PPGn2Man3Gn2Gal2.

[0042] Example 1

[0043] Expression and purification of oligosaccharyltransferase TbSTT3A.

[0044] Construction of vector: According to the nucleic acid sequence of Trypanosoma brucei STT3A (NCBI accession number: ADG03035.1) on NCBI, the vector was constructed using gene synthesis technology and fusion PCR, coated on the corresponding resistance screening plate, and the single clones with positive colony PCR were selected, and the plasmid was extracted and sent for sequencing.

[0045] The oligosaccharyl transferase TbSTT3A is fused with His and StrepII tags, and its nucleotide sequence is shown in SEQ ID NO.1;

[0046] The TbSTT3A gene fragment was constructed into the plasmid pFastBac1 to obtain the recombinant plasmid pFastBac1-8His-strepII-TEV-STT3A.

[0047] In the recombinant competent cell DH10BAac, the recombinant STT3A bacmid was extracted, and after PCR verification, the recombinant STT3A bacmid was transferred into the insect SF9 cells using a liposome transfection reagent. After 96 hours of culture, the cell culture supernatant was collected to obtain the first-generation virus. Then, the SF9 cells were infected with the first-generation virus. After 60 hours of culture, the cell culture supernatant was collected to obtain the second-generation virus. Finally, the SF9 cells were infected with the second-generation virus, and the cells were collected after 72 hours of culture.

[0048] The above cells were collected, lysed with lysis buffer (100mM HEPES (pH 7.5), 150mM NaCl, 1% DDM, 0.2% CHS, protease inhibitor), the protein was bound to StrepII beads, washed with washing buffer (100mM HEPES (pH 7.5), 150mM NaCl, 0.05% DDM, 0.005% CHS), and finally eluted with elution buffer (100mM HEPES (pH 7.5), 150mM NaCl, 0.05% DDM, 0.005% CHS, 50mM biotin); Figure 1 It showed that the TbSTTA protein had been successfully expressed and purified.

[0049] Example 2

[0050] Under the catalysis of oligosaccharyl transferase TbSTTA, the sugar chains in different fatty alcohol oligosaccharides are transferred to the model polypeptide (STD) to form N-glycopeptides containing different sugar chains:

[0051] The standard reaction conditions are as follows: a 50 μL reaction system contains 20 mM HEPES (pH 7.5), 10 mM MnCl2, 10 μM PPGn2Man3Gn / PPGn2Man3GnGal / PPGn2Man3Gn(Fuc)Gal / PPGn2Man3Gn2 / PPGn2Man3Gn2Gal2, 5 μM model peptide STD, and 20 nM TbSTT3A.

[0052] like Figure 2As shown in A, under the above standard reaction conditions, the reaction was carried out at 30°C for 2 to 12 hours. The reaction time was adjusted with the change of sugar form to ensure the reaction conversion rate. Inactivation was carried out at 100°C for 5 minutes, and the supernatant was collected by centrifugation to obtain a reaction solution containing GnMan3Gn2-STD, GalGnMan3Gn2-STD, GalGn(Fuc)Man3Gn2-STD, Gn2Man3Gn2-STD, and Gal2Gn2Man3Gn2-STD product glycopeptides. The instrument used for purification of the reaction solution was a high performance liquid chromatograph Alliance e2695 HPLC (Waters), the fluorescence detector used was a 2475FLR Detector (Waters), and the liquid chromatography column used was an amide column (TSKgel Amide-805μm 4.6×100mm). For the detection of 5CF-tagged glycopeptides, the excitation wavelength used by the fluorescence detector was 488nm, and the detection wavelength was 526nm ( Figure 2 B); elution conditions are acetonitrile (CH3CN)-ammonium acetate (NH4OAc) linear gradient elution (solution A: CH3CN; solution B: 0.2M NH4OAc pH 5.0; elution conditions: 0-3min, 85% A; 3-30min, 85%-40% A; 35min-38min, 40%-30% A; 38-40min, 30%-85% A; flow rate: 1mL / min) to separate substrates and products. The effluent is detected by a fluorescence detector, and the target peak is connected to the MALDI-TOF MS molecular weight for identification.

[0053] Figure 3 Results A to E show that the products GnMan3Gn2-STD, GalGnMan3Gn2-STD, GalGn(Fuc)Man3Gn2-STD, Gn2Man3Gn2-STD, Gal2Gn2Man3Gn2-STD and other glycopeptides were added with Na + The mass-to-charge ratio is consistent with the predicted molecular weight.

[0054] Example 3

[0055] Under the catalysis of oligosaccharyl transferase TbSTTA, the sugar chains in different fatty alcohol oligosaccharides are transferred to the human IgG polypeptide fragment IgG 297 On the surface, N-glycopeptides containing different sugar chains are formed:

[0056] The standard reaction conditions are as follows: 50 μL reaction system contains 20 mM HEPES (pH 7.5), 10 mM MnCl2, 10 μM PPGn2Man3Gn / PPGn2Man3GnGal / PPGn2Man3Gn(Fuc)Gal / PPGn2Man3Gn2 / PPGn2Man3Gn2Gal2, 5 μM human IgG 297 , 20nM TbSTT3A.

[0057] like Figure 4 As shown in A, under the above standard reaction conditions, the reaction was carried out at 30°C for 2 to 12 hours. The reaction time was adjusted according to the change of the glycoform to ensure the reaction conversion rate. The reaction was inactivated at 100°C for 5 minutes, and the supernatant was collected by centrifugation to obtain the GnMan3Gn2-IgG 297 , GalGnMan3Gn2-IgG 297 , GalGn(Fuc)Man3Gn2-IgG 297 , Gn2Man3Gn2-IgG 297 , Gal2Gn2Man3Gn2-IgG 297 The reaction solution was separated into substrate and product by high performance liquid chromatography ( Figure 4 B). The effluent was detected by a fluorescence detector and the target peak was simultaneously detected by MALDI-TOF MS molecular weight identification.

[0058] Figure 5 Results A to E show that the product is GnMan3Gn2-IgG 297 , GalGnMan3Gn2-IgG 297 , GalGn(Fuc)Man3Gn2-IgG 297 , Gn2Man3Gn2-IgG 297 , Gal2Gn2Man3Gn2-IgG 297 Equiglycopeptide plus Na + The mass-to-charge ratio is consistent with the predicted molecular weight.

[0059] Example 4

[0060] Under the catalysis of oligosaccharyl transferase TbSTTA, the sugar chains in different fatty alcohol oligosaccharides are transferred to the human EPO polypeptide fragment EPO 38 On the surface, N-glycopeptides containing different sugar chains are formed:

[0061] The standard reaction conditions are as follows: 50 μL reaction system contains 20 mM HEPES (pH 7.5), 10 mM MnCl2, 10 μM PPGn2Man3Gn / PPGn2Man3GnGal / PPGn2Man3Gn(Fuc)Gal / PPGn2Man3Gn2 / PPGn2Man3Gn2Gal2, 5 μM human EPO 38 , 20nM TbSTT3A.

[0062] like Figure 6 As shown in A, under the above standard reaction conditions, the reaction was carried out at 30°C for 2 to 12 hours. The reaction time was adjusted according to the change of sugar type to ensure the reaction conversion rate. The reaction was inactivated at 100°C for 5 minutes, and the supernatant was collected by centrifugation to obtain the GnMan3Gn2-EPO 38 , GalGnMan3Gn2-EPO 38 , GalGn(Fuc)Man3Gn2-EPO 38 , Gn2Man3Gn2-EPO 38 , Gal2Gn2Man3Gn2-EPO 38 The reaction solution was separated into substrate and product by high performance liquid chromatography ( Figure 6 B). The effluent was detected by a fluorescence detector and the target peak was simultaneously detected by MALDI-TOF MS molecular weight identification.

[0063] Figure 7 Results A to E show that the product is GnMan3Gn2-EPO 38 , GalGnMan3Gn2-EPO 38 , GalGn(Fuc)Man3Gn2-EPO 38 , Gn2Man3Gn2-EPO 38 , Gal2Gn2Man3Gn2-EPO 38 Equiglycopeptide plus Na + The mass-to-charge ratio is consistent with the predicted molecular weight.

[0064] Example 5

[0065] Under the catalysis of oligosaccharyl transferase TbSTTA, the sugar chains in oligosaccharides PPGn2Man3Gn2 and PPGn2Man3Gn2Gal2 were transferred to model peptide STD and human IgG, respectively. 297 , Human EPO 38 On the surface, N-glycopeptides containing different sugar chains are formed:

[0066] The standard reaction conditions are as follows: 50 μL reaction system contains 20 mM HEPES (pH 7.5), 10 mM MnCl2, 10 μM PPGn2Man3Gn2 / PPGn2Man3Gn2Gal2, 5 μM model peptide STD / human IgG 297 / Human EPO 38 、20nM TbSTT3A.

[0067] Under the above standard reaction conditions, the reaction was carried out at 30°C for 30 min and 1 h respectively. The reaction was inactivated at 100°C for 5 min and the supernatant was collected by centrifugation to obtain the supernatant containing Gn2Man3Gn2-STD, Gn2Man3Gn2-IgG 297 , Gn2Man3Gn2-EPO 38 ,Gal2Gn2Man3Gn2-STD,Gal2Gn2Man3Gn2-IgG 297 , Gal2Gn2Man3Gn2-EPO 38 The reaction solution was separated into substrate and product by high performance liquid chromatography ( Figure 8 A, B). The effluent was detected by a fluorescence detector, and the target peak was simultaneously connected to perform MALDI-TOF MS molecular weight identification.

[0068] Figure 8 A The results showed that the conversion rate of PPGn2Man3Gn2 catalyzed by oligosaccharyltransferase STT3A to different polypeptides did not reach 100% within 30 minutes.

[0069] Figure 8 B The results showed that the conversion rate of PPGn2Man3Gn2Gal2 catalyzed by oligosaccharyltransferase STT3A to different polypeptides did not reach 100% within 1 hour.

[0070] The invention expresses and purifies the oligosaccharyl transferase TbSTT3A from Trypanosoma brucei, and successfully prepares GnMan3Gn2-STD, GalGnMan3Gn2-STD, GalGn(Fuc)Man3Gn2-STD, Gn2Man3Gn2-STD, Gal2Gn2Man3Gn2-STD and GnMan3Gn2-IgG by using the oligosaccharyl transfer reaction catalyzed by TbSTT3A in vitro. 297 , GalGnMan3Gn2-IgG 297 , GalGn(Fuc)Man3Gn2-IgG 297 , Gn2Man3Gn2-IgG 297 , Gal2Gn2Man3Gn2-IgG 297 ;GnMan3Gn2-EPO38 , GalGnMan3Gn2-EPO 38 , GalGn(Fuc)Man3Gn2-EPO 38 , Gn2Man3Gn2-EPO 38 , Gal2Gn2Man3Gn2-EPO 38 A series of glycopeptides containing human complex N-glycans provide new strategies for the efficient assembly of uniform glycopeptides / glycoproteins containing complex N-glycans, which is of great significance for comprehensively and accurately exploring the biological activity of human glycoproteins and promoting the development of glycochemistry and glycobiology.

[0071] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.

Claims

1. An in vitro assembly method of human composite N-glycopeptide, characterized in that: include, Expression of Trypanosoma brucei-derived oligosaccharyltransferase TbSTT3A in insect cells; Using oligosaccharyl transferase TbSTT3A to catalyze the transfer of oligosaccharides from fatty alcohol oligosaccharides containing N-sugar chains to polypeptides, humanized composite N-glycopeptides were obtained. Wherein, the oligosaccharyl transferase TbSTT3A gene has a nucleotide sequence as shown in SEQ ID NO.

1.

2. The in vitro assembly method of human composite N-glycopeptide according to claim 1, characterized in that: The catalytic reaction system also contains HEPES and MnCl2; Relative to the 50 μL system, the final concentration of HEPES is 20 mM, the final concentration of MnCl2 is 10 mM, the final concentration of polypeptide is 10 μM, the final concentration of fatty alcohol oligosaccharide is 10-20 μM, the final concentration of TbSTT3A is 20 nM, and the reaction time is 2-12 h.

3. The in vitro assembly method of human composite N-glycopeptide according to claim 1, characterized in that: The fatty alcohol oligosaccharides containing N-sugar chains are various fatty alcohol oligosaccharides obtained by using PPGn2 as a starting substrate and catalyzed by recombinant glycosyltransferases Alg1, Alg2, GnT-I, GnT-II, GalT and FuT expressed by Escherichia coli.

4. The in vitro assembly method of human composite N-glycopeptide according to claim 3, characterized in that: The fatty alcohol oligosaccharide containing N-sugar chain is selected from one of PPGn2Man3Gn, PPGn2Man3GnGal, PPGn2Man3Gn(Fuc)Gal, PPGn2Man3Gn2, and PPGn2Man3Gn2Gal2.

5. The in vitro assembly method of human complex N-glycopeptide according to any one of claims 1 to 4, characterized in that: The polypeptide includes a model polypeptide STD and a human polypeptide, and the human polypeptide includes one of a human IgG polypeptide fragment and a human EPO polypeptide fragment.

6. The in vitro assembly method of human composite N-glycopeptide according to claim 5, characterized in that: The model polypeptide STD has a polypeptide sequence of 5CF-GSDANYTYTQ-NH2.

7. The in vitro assembly method of human complex N-glycopeptide according to claim 5, characterized in that: The human IgG polypeptide fragment is a human IgG polypeptide 297 , whose polypeptide sequence is 5CF-EEQYN 297 STYRV-NH2.

8. The in vitro assembly method of human composite N-glycopeptide according to claim 5, characterized in that: The human EPO polypeptide fragment is a human polypeptide EPO 38 , whose polypeptide sequence is 5CF-SLNEN 38 ITVPD-NH2.

9. The in vitro assembly method of human composite N-glycopeptide according to any one of claims 1 to 4 and 6 to 8, characterized in that: The oligosaccharyl transferase TbSTT3A is an oligosaccharyl transferase STT3A with 8*His and StrepII tags fused to the N-terminus, and the oligosaccharyl transferase STT3A is derived from Trypanosoma brucei.

10. The in vitro assembly method of human complex N-glycopeptide according to claim 9, characterized in that: The method for expressing the oligosaccharyl transferase TbSTT3A from Trypanosoma brucei in insect cells comprises: According to the nucleic acid sequence of oligosaccharyl transferase STT3A from Trypanosoma brucei, a vector was constructed using gene synthesis technology and fusion PCR, and then coated on the corresponding resistance screening plate, and the single clones with positive colony PCR were selected, and the plasmid was extracted and sent for sequencing to obtain oligosaccharyl transferase TbSTT3A; The TbSTT3A gene fragment was constructed into the plasmid pFastBac1 to obtain the recombinant plasmid pFastBac1-8His-strepII-TEV-STT3A; The recombinant plasmid pFastBac1-strepII-TEV-STT3A was transformed into the competent cell DH10BAac, and the recombinant STT3A bacmid was extracted. After PCR verification, the recombinant STT3A bacmid was transferred into insect SF9 cells using a liposome transfection reagent to obtain the first-generation virus. The first-generation virus was then used to infect SF9 cells to obtain the second-generation virus. Finally, the second-generation virus was used to infect SF9 cells. After culture, the cells were collected, lysed, and purified by Strep affinity chromatography. The expression and purity of the TbSTT3A protein were confirmed by SDS-PAGE.